Travere Therapeutics (TVTX) Revenue & Revenue Breakdown
Travere Therapeutics Revenue Highlights
Latest Revenue (Y)
$145.24M
Latest Revenue (Q)
$54.12M
Main Segment (Y)
License
Travere Therapeutics Revenue by Period
Travere Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $145.24M | -31.50% |
| 2022-12-31 | $212.02M | -6.80% |
| 2021-12-31 | $227.49M | 14.71% |
| 2020-12-31 | $198.32M | 13.11% |
| 2019-12-31 | $175.34M | 6.75% |
| 2018-12-31 | $164.25M | 6.01% |
| 2017-12-31 | $154.94M | 15.98% |
| 2016-12-31 | $133.59M | 33.74% |
| 2015-12-31 | $99.89M | 254.19% |
| 2014-12-31 | $28.20M | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-02-29 | - | 100.00% |
| 2011-02-28 | - | 100.00% |
| 2010-02-28 | - | 100.00% |
| 2009-02-28 | - | - |
Travere Therapeutics generated $145.24M in revenue during NA 2023, up -31.50% compared to the previous quarter, and up 88.43% compared to the same period a year ago.
Travere Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $54.12M | 30.80% |
| 2024-03-31 | $41.37M | -8.18% |
| 2023-12-31 | $45.06M | 21.47% |
| 2023-09-30 | $37.09M | -37.86% |
| 2023-06-30 | $59.70M | 4.74% |
| 2023-03-31 | $56.99M | 2.01% |
| 2022-12-31 | $55.87M | 4.43% |
| 2022-09-30 | $53.50M | -1.24% |
| 2022-06-30 | $54.17M | 11.71% |
| 2022-03-31 | $48.49M | -15.31% |
| 2021-12-31 | $57.25M | -16.08% |
| 2021-09-30 | $68.22M | 24.90% |
| 2021-06-30 | $54.62M | 15.21% |
| 2021-03-31 | $47.41M | -7.01% |
| 2020-12-31 | $50.98M | -0.31% |
| 2020-09-30 | $51.14M | 5.59% |
| 2020-06-30 | $48.43M | 1.38% |
| 2020-03-31 | $47.77M | 2.32% |
| 2019-12-31 | $46.69M | 5.21% |
| 2019-09-30 | $44.37M | -0.75% |
| 2019-06-30 | $44.71M | 12.98% |
| 2019-03-31 | $39.57M | -9.60% |
| 2018-12-31 | $43.77M | 7.53% |
| 2018-09-30 | $40.71M | -1.53% |
| 2018-06-30 | $41.34M | 7.56% |
| 2018-03-31 | $38.43M | -8.88% |
| 2017-12-31 | $42.18M | 4.55% |
| 2017-09-30 | $40.34M | 3.97% |
| 2017-06-30 | $38.80M | 15.41% |
| 2017-03-31 | $33.62M | -9.93% |
| 2016-12-31 | $37.33M | 9.96% |
| 2016-09-30 | $33.95M | 1.90% |
| 2016-06-30 | $33.31M | 14.83% |
| 2016-03-31 | $29.01M | -4.73% |
| 2015-12-31 | $30.45M | 8.72% |
| 2015-09-30 | $28.00M | 16.36% |
| 2015-06-30 | $24.07M | 38.55% |
| 2015-03-31 | $17.37M | 23.34% |
| 2014-12-31 | $14.08M | 68.71% |
| 2014-09-30 | $8.35M | 45.40% |
| 2014-06-30 | $5.74M | 20479.69% |
| 2014-03-31 | $27.90K | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-11-30 | - | 100.00% |
| 2012-08-31 | - | 100.00% |
| 2012-05-31 | - | 100.00% |
| 2012-02-29 | - | 100.00% |
| 2011-11-30 | - | 100.00% |
| 2011-08-31 | - | 100.00% |
| 2011-05-31 | - | 100.00% |
| 2011-02-28 | - | 100.00% |
| 2010-11-30 | - | 100.00% |
| 2010-08-31 | - | 100.00% |
| 2010-05-31 | - | - |
Travere Therapeutics generated $54.12M in revenue during Q2 2024, up 30.80% compared to the previous quarter, and up 94.95% compared to the same period a year ago.
Travere Therapeutics Revenue Breakdown
Travere Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| License | $17.70M | - | - | - | - |
| Active Pharmaceutical Ingredient | $3.30M | - | - | - | - |
| Product | - | $200.53M | $210.78M | - | - |
| Tiopronin Products | - | $97.97M | $115.12M | $108.88M | - |
| Bile Acid Products | - | $102.56M | $95.65M | $89.44M | $79.70M |
| Thiola License | - | - | - | - | $95.64M |
Travere Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (84.29%), and Active Pharmaceutical Ingredient (15.71%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License | $1.94M | $1.39M | $14.54M | $3.16M | $2.67M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | $52.18M | $39.98M | $57.01M | $50.28M | $52.34M | $50.79M | $50.95M | $46.44M | $54.58M | $54.17M | - | - | - | - | - | - | - | - | - | - |
| Active Pharmaceutical Ingredient | - | - | - | $3.30M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Bile Acid Products | - | - | - | - | $27.50M | $26.11M | $26.53M | $25.42M | $25.53M | $25.07M | $24.35M | $24.97M | $21.96M | $22.67M | $22.91M | $21.57M | $22.28M | $20.44M | $19.94M | - |
| Tiopronin Products | - | - | - | - | $26.05M | $21.17M | $25.82M | $25.37M | $25.42M | $21.37M | $29.82M | $29.64M | $25.44M | $28.31M | $28.23M | $26.86M | $25.49M | $24.43M | - | - |
Travere Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (96.42%), and License (3.58%).
Travere Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 22 |
|---|---|
| FRANCE | $8.00M |
Travere Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 22: FRANCE (100.00%).
Travere Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| TVTX | Travere Therapeutics | $145.24M | $54.12M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| CYTK | Cytokinetics | $7.53M | $249.00K |
| FIXX | Q32 Bio | $1.16M | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| GPCR | Structure Therapeutics | - | - |
| PCVX | Vaxcyte | - | - |
| NUVL | Nuvalent | - | - |
| COGT | Cogent Biosciences | - | - |
| DICE | DICE Therapeutics | - | - |
| CERE | Cerevel Therapeutics | - | - |
| VTYX | Ventyx Biosciences | - | - |
| AKRO | Akero Therapeutics | - | - |
TVTX Revenue FAQ
What is Travere Therapeutics’s yearly revenue?
Travere Therapeutics's yearly revenue for 2023 was $145.24M, representing a decrease of -31.50% compared to 2022. The company's yearly revenue for 2022 was $212.02M, representing a decrease of -6.80% compared to 2021. TVTX's yearly revenue for 2021 was $227.49M, representing an increase of 14.71% compared to 2020.
What is Travere Therapeutics’s quarterly revenue?
Travere Therapeutics's quarterly revenue for Q2 2024 was $54.12M, a 30.80% increase from the previous quarter (Q1 2024), and a -9.35% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $41.37M, a -8.18% decrease from the previous quarter (Q4 2023), and a -27.41% decrease year-over-year (Q1 2023). TVTX's quarterly revenue for Q4 2023 was $45.06M, a 21.47% increase from the previous quarter (Q3 2023), and a -19.35% decrease year-over-year (Q4 2022).
What is Travere Therapeutics’s revenue growth rate?
Travere Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -36.16%, and for the last 5 years (2019-2023) was -17.17%.
What are Travere Therapeutics’s revenue streams?
Travere Therapeutics's revenue streams in c 23 are License, and Active Pharmaceutical Ingredient. License generated $17.7M in revenue, accounting 84.29% of the company's total revenue Active Pharmaceutical Ingredient generated $3.3M in revenue, accounting 15.71% of the company's total revenue
What is Travere Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Travere Therapeutics was License. This segment made a revenue of $17.7M, representing 84.29% of the company's total revenue.